Get the Stockscreener App
5.765
0.96%
0.055
Galectin Therapeutics Inc stock is traded at $5.765, with a volume of 68,902.
It is up +0.96% in the last 24 hours and up +10.23% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$5.71
Open:
$5.74
24h Volume:
68,902
Relative Volume:
0.20
Market Cap:
$370.72M
Revenue:
-
Net Income/Loss:
$-45.08M
P/E Ratio:
-7.8973
EPS:
-0.73
Net Cash Flow:
$-33.68M
1W Performance:
+0.44%
1M Performance:
+10.23%
6M Performance:
+350.39%
1Y Performance:
+108.12%
1-Day Range:
$5.74
$5.85
1-Week Range:
$5.23
$6.1558
52-Week Range:
$0.726
$6.55
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
5.75 | 368.14M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
431.64 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.05 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.75 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
919.65 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.33 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Resumed | H.C. Wainwright | Buy |
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Will Galectin Therapeutics Inc. stock sustain high P E ratiosTrade Volume Summary & Weekly High Potential Alerts - BỘ NỘI VỤ
Galectin Therapeutics: NAVIGATE Data Validates The Fibrosis Thesis - Seeking Alpha
Wealthspire Advisors LLC Buys 81,144 Shares of Galectin Therapeutics Inc. $GALT - MarketBeat
How Galectin Therapeutics Inc. stock reacts to Fed rate cutsDip Buying & Stepwise Trade Execution Plans - newser.com
How Galectin Therapeutics Inc. (PHPN) stock trades pre earnings2025 Support & Resistance & Fast Entry Momentum Trade Alerts - newser.com
What sentiment indicators say about Galectin Therapeutics Inc. stockTrade Analysis Summary & Real-Time Buy Zone Alerts - newser.com
Will Galectin Therapeutics Inc. (PHPN) stock beat international competitionTrade Entry Report & Verified Swing Trading Watchlist - newser.com
Can Galectin Therapeutics Inc. (PHPN) stock double in coming yearsBull Run & Technical Pattern Recognition Alerts - newser.com
Applying Elliott Wave Theory to Galectin Therapeutics Inc.Quarterly Profit Review & Step-by-Step Trade Execution Guides - newser.com
Will Galectin Therapeutics Inc. (PHPN) stock hit analyst forecasts2025 Institutional Moves & Breakout Confirmation Alerts - newser.com
Galectin Therapeutics Insider Sold Shares Worth $478,849, According to a Recent SEC Filing - MarketScreener
CFO Callicutt Sells 77,920 ($478.8K) Of Galectin Therapeutics Inc [GALT] - TradingView
CEO Lewis Sells 22,463 ($136.4K) Of Galectin Therapeutics Inc [GALT] - TradingView
[Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity - Stock Titan
What valuation multiples suggest for Galectin Therapeutics Inc. stock2025 Fundamental Recap & Consistent Profit Alerts - newser.com
Holdings of Galectin Therapeutics Inc (GALT) are aligned with the stars - Setenews
How robust is Galectin Therapeutics Inc. (PHPN) stock financial positionGap Up & Real-Time Buy Signal Alerts - newser.com
How big funds are accumulating Galectin Therapeutics Inc. (PHPN) stock2025 Macro Impact & Low Drawdown Investment Strategies - newser.com
Galectin Therapeutics (NASDAQ:GALT) Insider Sells 121,117 Shares - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Releases Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Can you recover from losses in Galectin Therapeutics Inc.Weekly Stock Summary & Entry Point Confirmation Signals - newser.com
Galectin Therapeutics reports Q4 EPS (13c) vs (18c) last year - MSN
Will Galectin Therapeutics Inc. (PHPN) stock beat growth indexesWeekly Volume Report & Free AI Powered Buy and Sell Recommendations - newser.com
Galectin Therapeutics (NASDAQ:GALT) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Galectin Therapeutics Inc Stock (GALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LEWIS JOEL | President and CEO |
Nov 18 '25 |
Option Exercise |
2.39 |
6,783 |
16,211 |
839,375 |
| LEWIS JOEL | President and CEO |
Nov 17 '25 |
Sale |
6.04 |
15,680 |
94,643 |
832,592 |
| LEWIS JOEL | President and CEO |
Nov 18 '25 |
Sale |
6.15 |
6,783 |
41,723 |
832,592 |
| CALLICUTT JACK W | Chief Financial Officer |
Nov 18 '25 |
Option Exercise |
1.64 |
46,310 |
75,851 |
35,714 |
| CALLICUTT JACK W | Chief Financial Officer |
Nov 17 '25 |
Option Exercise |
1.38 |
31,610 |
43,706 |
27,315 |
| CALLICUTT JACK W | Chief Financial Officer |
Nov 18 '25 |
Sale |
6.22 |
46,310 |
288,187 |
7,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Nov 17 '25 |
Sale |
6.03 |
31,610 |
190,662 |
7,614 |
| Jamil Khurram | Chief Medical Officer |
Nov 13 '25 |
Option Exercise |
2.17 |
99,250 |
215,038 |
45,979 |
| Jamil Khurram | Chief Medical Officer |
Nov 13 '25 |
Sale |
5.47 |
121,117 |
662,510 |
4,479 |
0.55%
1.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):